Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have earned an average rating of “Hold” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $10.78.

Several research firms recently commented on ZNTL. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research note on Monday, August 12th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 target price on the stock in a research report on Monday, August 12th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th.

Zentalis Pharmaceuticals Stock Up 21.6 %

Shares of NASDAQ:ZNTL opened at $3.32 on Monday. Zentalis Pharmaceuticals has a 12-month low of $2.66 and a 12-month high of $18.24. The business has a 50 day moving average of $3.30 and a 200-day moving average of $6.00. The stock has a market cap of $236.08 million, a PE ratio of -1.22 and a beta of 1.74.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Friday, August 9th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same quarter last year, the company posted ($1.85) earnings per share. Equities research analysts expect that Zentalis Pharmaceuticals will post -3.02 earnings per share for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its position in shares of Zentalis Pharmaceuticals by 20.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after buying an additional 585,644 shares during the last quarter. Decheng Capital LLC raised its stake in Zentalis Pharmaceuticals by 46.2% during the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock worth $12,558,000 after acquiring an additional 970,859 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Zentalis Pharmaceuticals by 5.8% in the second quarter. Primecap Management Co. CA now owns 1,232,340 shares of the company’s stock worth $5,040,000 after acquiring an additional 67,730 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock valued at $2,706,000 after purchasing an additional 399,745 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Zentalis Pharmaceuticals by 15.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 333,719 shares of the company’s stock valued at $1,365,000 after purchasing an additional 43,839 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.